The latest price target for Recursion Pharmaceuticals (NASDAQ:RXRX) was reported by Needham on June 25, 2024. The analyst firm set a price target for $17.00 expecting RXRX to rise to within 12 months (a possible 130.98% upside). 18 analyst firms have reported ratings in the last year.

The latest analyst rating for Recursion Pharmaceuticals (NASDAQ:RXRX) was provided by Needham, and Recursion Pharmaceuticals reiterated their buy rating.

There is no last upgrade for Recursion Pharmaceuticals

The last downgrade for Recursion Pharmaceuticals Inc happened on April 18, 2022 when B of A Securities changed their price target from N/A to N/A for Recursion Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Recursion Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Recursion Pharmaceuticals was filed on June 25, 2024 so you should expect the next rating to be made available sometime around June 25, 2025.

While ratings are subjective and will change, the latest Recursion Pharmaceuticals (RXRX) rating was a reiterated with a price target of $17.00 to $17.00. The current price Recursion Pharmaceuticals (RXRX) is trading at is $7.36, which is out of the analyst’s predicted range.